Otlertuzumab ( TRU ‐016), an anti‐ CD 37 monospecific ADAPTIR ™ therapeutic protein, for relapsed or refractory NHL patients-Reference-Cited by-同舟云学术

Otlertuzumab ( TRU ‐016), an anti‐ CD 37 monospecific ADAPTIR ™ therapeutic protein, for relapsed or refractory NHL patients

Author:

Pagel John M.¹,Spurgeon Stephen E.²,Byrd John C.³,Awan Farrukh T.⁴,Flinn Ian W.⁵,Lanasa Mark C.⁶,Eisenfeld Amy J.⁷,Stromatt Scott C.⁷,Gopal Ajay K.¹

Affiliation:

1. Fred Hutchinson Cancer Research Center University of Washington Seattle WA USA

2. Department of Hematology and Medical Oncology Oregon Health & Science University Knight Cancer Institute Portland OR USA

3. Division of Hematology and Comprehensive Cancer Center The Ohio State University Columbus OH USA

4. Division of Hematology‐Oncology Georgia Regents University Augusta GA USA

5. Sarah Cannon Research Institute Nashville TN USA

6. Duke University Medical Center Durham NC USA

7. Emergent Product Development Seattle WA USA

Publisher

Wiley

Subject

Hematology

Link

Reference32 articles.

4. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray;Belov L.;Cancer Research,2001

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献